甲磺吡脲/甲磺双环脲/格列齐特/甲磺格脲

• 产品编号：G0116
• 中文名称：Gliclazide/达美康/甲磺吡脲/甲磺双环脲/格列齐特/优哒灵/来克胰/甲磺格脲
• 英文名称：Gliclazide
• 英文别名:Gliclazide /Diamicron/Dramion/Nordialex/1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea
• CAS号:21187-98-4
• 分子式:C15H21N3O3S
• 分子量:323.41
• 纯度:≥98%
• EC号:244-260-5
• MDL号:MFCD00409893

Application
Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Biochem/physiol Actions
Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases